These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 21972401

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH, Shah P, Kinnaird T, Pinto Slottow TL, Roy PK, Okabe T, Bonello L, de Labriolle A, Smith KA, Torguson R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R.
    Am J Cardiol; 2008 Jul 15; 102(2):160-4. PubMed ID: 18602514
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
    Bangalore S, Pencina MJ, Kleiman NS, Cohen DJ.
    Circ Cardiovasc Interv; 2014 Jun 15; 7(3):365-73. PubMed ID: 24736878
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.
    Pinto DS, Ogbonnaya A, Sherman SA, Tung P, Normand SL.
    Circ Cardiovasc Qual Outcomes; 2012 Jan 15; 5(1):52-61. PubMed ID: 22235065
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G.
    Am J Cardiol; 2012 Aug 15; 110(4):478-84. PubMed ID: 22583760
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
    Kaul U, Dua A, Sethi AK, Arambam P, Seth A.
    Indian Heart J; 2015 Aug 15; 67(4):311-7. PubMed ID: 26304562
    [Abstract] [Full Text] [Related]

  • 12. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
    Abtahian F, Waldo S, Jang IK.
    Catheter Cardiovasc Interv; 2015 Sep 15; 86(3):390-6. PubMed ID: 25753749
    [Abstract] [Full Text] [Related]

  • 13. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, Stone GW.
    Circ Cardiovasc Interv; 2012 Oct 15; 5(5):705-12. PubMed ID: 23048052
    [Abstract] [Full Text] [Related]

  • 14. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL.
    Hosp Pract (1995); 2010 Nov 15; 38(4):138-46. PubMed ID: 21068538
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention.
    Rehmani A, Judkins C, Whelan A, Nguyen M, Schultz C.
    Heart Lung Circ; 2017 Dec 15; 26(12):1277-1281. PubMed ID: 28377232
    [Abstract] [Full Text] [Related]

  • 17. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ, Lee RC, Gaglia MA, Torguson R, Garcia-Garcia HM, Pichard AD, Satler LF, Waksman R.
    Cardiovasc Revasc Med; 2016 Dec 15; 17(8):535-545. PubMed ID: 27842901
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of bivalirudin for percutaneous coronary intervention with rotational atherectomy.
    Delhaye C, Wakabayashi K, Maluenda G, Ben-Dor I, Torguson R, Xue Z, Suddath WO, Satler LF, Pichard AD, Kent KM, Lindsay J, Waksman R.
    J Interv Cardiol; 2010 Jun 15; 23(3):223-9. PubMed ID: 20636842
    [Abstract] [Full Text] [Related]

  • 19. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
    Zhang Y, Zhang Y, Liu Z, Zhang B, Liu G, Chen K.
    Biomed Pharmacother; 2020 Oct 15; 130():110758. PubMed ID: 34321166
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.